Compare IMUX & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMUX | ASRT |
|---|---|---|
| Founded | 2016 | 1995 |
| Country | United States | United States |
| Employees | 66 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.2M | 76.0M |
| IPO Year | 2013 | 2004 |
| Metric | IMUX | ASRT |
|---|---|---|
| Price | $1.16 | $11.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $4.25 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 3.2M | 22.0K |
| Earning Date | 05-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.00 | ★ 95.07 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $124,961,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.51 | $0.51 |
| 52 Week High | $1.51 | $12.95 |
| Indicator | IMUX | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 56.81 | 55.43 |
| Support Level | $0.64 | $11.05 |
| Resistance Level | $1.17 | $12.45 |
| Average True Range (ATR) | 0.13 | 0.47 |
| MACD | 0.00 | -0.12 |
| Stochastic Oscillator | 44.67 | 60.00 |
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.